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Abstract
Background: The additional use of radiotherapy has changed the treatment of locally advanced
rectal cancer (LARC) dramatically. But a major achievement has been the development of total
mesorectal excision (TME) as a surgical standard and the recognition that the surgeon is the
predominant prognostic factor. The benefit of preoperative hypofractionated radiotherapy (SCRT;
five fractions each of 5 Gy), initially established by the Swedish Rectal Cancer Trial, has been
demonstrated in conjunction with TME by the Dutch Colorectal Cancer Group. The concept of
combined neoadjuvant radiochemotherapy (conventional radiation of about 50 Gy with
chemotherapy) has not been compared over surgery alone with TME. However, the German
Rectal Cancer Study Group recently demonstrated that preoperative radiochemotherapy (RCT)
was better than postoperative radiochemotherapy in terms of local control.
Methods and design: Patients with histological proven rectal cancer staged T2N+ or T3 are
randomized to receive either SCRT (25 Gy in five fractions of 5 Gy) plus TME-surgery within 5 days
or RCT (50.4 Gy in 28 fractions of 1.8 Gy, continuous infusion 5-fluorouracil) plus TME-surgery 4–
6 weeks later. All patients receive adjuvant chemotherapy (12 weeks continuous infusional 5-FU)
and are followed up for 5 years. TME-quality is independently documented by the surgeon and the
pathologist. Hypothesis of the study is that RCT is superior to SCRT in terms of local recurrence
after five years. Secondary endpoints are overall survival, disease-free survival, complete resection
rate (R0 resection), rate of sphincter saving resection, acute and late toxicity (radiation related side
effects), and quality of life (including long term bowel function).
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BMC Cancer 2009, 9:50 http://www.biomedcentral.com/1471-2407/9/50Discussion: Similar long-term survival, local control and late morbidity have been reported for
both concepts of preoperative therapy in non-comparative studies. In addition to other ongoing
(and recently published) comparative trials we include a larger number of patients for adequate
power, apply quality-controlled TME and try to avoid the adjuvant treatment bias by mandatory
adjuvant chemotherapy in both groups. Further more, stratification of the initially planned surgical
procedure and sphincter-preservation will generate valid evidence whether RCT will allow a less
aggressive (sphincter saving) surgical approach.
Background
Colorectal cancer (CRC) is the second most frequent
malignant disease in western countries. In Germany, more
than 70,000 new cases occur yearly and approximately
40% are located in the rectum [1]. Despite major efforts in
prevention/screening and significant improvements in
surgical, radiation and medical therapy CRC is still one of
the leading causes of cancer mortality.
Besides survival, a major problem in locally advanced rec-
tal cancer (LARC) is the thread of local recurrence, not
only because of the limited therapeutic options but espe-
cially because of the impaired quality of life due to the
intense pain and uncontrolled soiling (caused by faecal
incontinence and/or mucus/blood from the tumour).
The last decade has brought advances in multimodality
treatment of LARC. After the endorsement of postopera-
tive adjuvant radiochemotherapy by a National Cancer
Institute Consensus Conference in 1990 [2], several rand-
omized studies reported lower rates of local failure with
preoperative radiotherapy than with surgery alone [3,4].
Furthermore, the Swedish Rectal Cancer Trial, evaluating
preoperative short-course radiotherapy (SCRT), found an
advantage in overall survival compared to surgery alone
[5]. The recently published results from the CAO/ARO/
AIO-94 trial report that preoperative combined radioche-
motherapy (RCT) is superior to postoperative RCT in
terms of outcome [6]. A major achievement in the treat-
ment of LARC has been the development of total mesorec-
tal excision (TME) as a surgical standard [7]. So far, the
only study evaluating preoperative therapy together with
a documented quality controlled TME-surgery is the
Dutch Colorectal Cancer Group study. SCRT with TME
was superior to TME alone in terms of local recurrence,
whereas overall survival was similar in both groups [4].
The EORTC 22921 trial, already started in the late nineties
of the last century and published recently, showed a sim-
ilar reduction in local recurrence whether 5FU/leucovorin
chemotherapy was given with pre-operative radiotherapy,
after preoperative radiotherapy plus surgery, or both [8].
In Europe, there is still much debate about the two differ-
ent approaches to preoperative therapy – SCRT and "long-
course" RCT. Although having undoubted weakness, a
recently published study of the Polish Colorectal Study
Group comparing the two approaches reported no superi-
ority for RCT in terms of either overall or local control [9].
Even in the U.S., there is now increasing demand in con-
sidering the use of SCRT in order to better stratify for adju-
vant therapy, because of the low probability of
downsizing and therefore "unchanged" initial TN-staging
[10].
Our study, the Berlin Rectal Cancer Trial (BRCT) was
planned in 2003 and enrolled the first patient in 2004.
After initiation of the polish trial and the BRCT in Europe,
a comparative trial very similar to the BRCT was con-
ducted in Australia. This TROG/AGITG trial recently
closed recruitment after enrolling some three hundred
patients. In addition to the recently published polish trial
we include a larger number of patients for adequate
power, applied quality-controlled TME and tried to avoid
the adjuvant treatment bias by mandatory adjuvant chem-
otherapy in both groups. Further more, stratification of
the initially planned surgical procedure and sphincter-
preservation will generate valid evidence whether RCT
will allow a less aggressive (sphincter saving) surgical
approach.
Hypothesis of our study is that RCT is superior to SCRT in
terms of local recurrence after five years.
Methods and design
Study design
The study is a two-arm prospective randomised multicen-
tre trial. The treatment algorithm is depicted in Figure 1.
Study objectives
The study compares the value of the two most common
preoperative therapy regimens in LARC in terms of local
recurrence. The primary outcome measure is local recur-
rence after a follow up of five years. The secondary out-
come measures are overall survival, disease-free survival
and quality of life (including long term bowel function)
after a median follow-up of five years. Further more, sec-
ondary endpoints are the complete resection rate (R0
resection) and the rate of sphincter saving resection, bothPage 2 of 6
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and late toxicity (radiation related side effects) will be
observed after a median follow-up of five years.
Trial organization
BRCT has been designed by the Department of Surgery
and Surgical Oncology (Charité, Campus Berlin-Buch) in
cooperation with the Department of Radiotherapy (Char-
ité, Campus Berlin-Buch and Campus Mitte), the Depart-
ment of Haematology, Oncology and Tumorimmunology
(Charité, Campus Berlin-Buch) and the Institute of Medi-
cal Informatics and Biometry (Charité), Berlin, Germany.
The trial is an investigator initiated trial. The BRCT is sup-
ported by the Berlin Cancer Society (Berliner Krebsgesells-
chaft e.V.).
Coordination
The trial is coordinated by the clinical trial office of the
Charité Comprehensive Cancer Center, Charité, Berlin.
The clinical trial office is responsible for overall trial man-
agement, trial registration (EudraCT Number 2004-
001606-27; Current Controlled Trials
ISRCTN56463377), database management, quality assur-
ance including monitoring, reporting and for the scientific
program of all trial related meetings supported by the Ber-
liner Krebsgesellschaft e.V..
Investigators
Patients are recruited in the following centres in Germany:
Robert-Rössle-Klinik Charité, Berlin; Helios Klinikum
Emil-von-Behring, Berlin; Oskar-Ziethen-Krankenhaus,
Berlin; Virchow-Klinkum Charité, Berlin; DRK-Klinikum
Westend, Berlin; Krankenhaus Düsseldorf-Gerresheim,
Düsseldorf; DRK-Krankenhaus Luckenwalde, Lucken-
walde; Schlossparkklinik, Berlin; Helios Klinikum
Schwerin, Schwerin; St.-Joseph-Krankenhaus, Berlin;
DRK-Kliniken Köpenick, Berlin; DRK-Klinikum Westend,
Berlin; Dominikus Krankenhaus, Berlin; Vivantes Hum-
boldt Klinikum, Berlin; Universitätsklinikum Münster,
Münster; Vivantes Klinikum Neukölln, Berlin; Kreiskrank-
enhaus Prignitz, Prignitz; Evangelisches Krankenhaus
Königin Elisabeth Herzberge, Berlin; Krankenhaus Wald-
friede, Berlin; St. Hedwig Klinikum, Berlin; Gemeinschaft-
skrankenhaus Havelhöhe, Berlin; Klinikum Ludwigsburg,
Ludwigsburg; Universitätsklinikum Düsseldorf, Düssel-
dorf; Benjamin-Franklin-Klinikum Charité, Berlin; Martin
Luther Krankenhaus, Berlin; Klinikum Ernst von Berg-
mann, Potsdam; Unfallkrankenhaus Marzahn, Berlin;
Caritas Klinik Maria Heimsuchung, Berlin; Universitätsk-
linikum Essen, Essen; Klinikum Sindelfingen-Böblingen,
Böblingen; Evangelisch-Freikirchliches-Krankenhaus Ber-
nau, Bernau; Helios Klinikum Berlin, Berlin; Vivantes
Klinikum am Urban, Berlin; Universitätsklinikum Leip-
zig, Leipzig; Vivantes Klinikum Spandau, Berlin; Henriet-
Treatment algorithmFigure 1
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Hannover, Hannover; Helios Klinikum Wuppertal, Wup-
pertal; Krankenhaus Hedwigshöhe, Berlin.
On-site monitoring
During recruitment of patients monitoring on site is per-
formed according to good clinical practice (GCP) guide-
lines. The data management will be performed by the
clinical trial office of the Charité Comprehensive Cancer
Center, Charité, Berlin.
Ethics, informed consent and safety
The final protocol was approved by the ethics committee
of the Charité, Berlin, Germany (ref: AA3/03/38). It is cer-
tified and recommended by the German Cancer Society
(Deutsche Krebsgesellschaft e.V., "Gütesiegel A", 29th
September 2003). This study complies with the Helsinki
Declaration in its recent version, the Medical Association's
professional code of conduct, the principles of Good Clin-
ical Practice (GCP) guidelines and the Federal Data Pro-
tection Act. The trial will also be carried out in keeping
with local legal and regulatory requirements. The medical
secrecy and the Federal Data Protection Act will be fol-
lowed. Written informed consent is obtained from each
patient in oral and written form before inclusion in the
trial and the nature, scope, and possible consequences of
the trial have been explained by a physician. The investi-
gator will not undertake any measures specifically
required only for the clinical trial until valid consent has
been obtained.
Statistics
Local recurrence after five years follow up has been chosen
as primary endpoint. Survival in the regarded treatment
arms will be graphically demonstrated by using Kaplan-
Meier estimates. Univariate Log-Rank tests as well as mul-
tivariate Cox' regression analyses will be conducted for the
analysis of primary and secondary endpoints. The altera-
tion of hazard ratios in time will be modelled [11]. Prov-
ing a two-sided hypothesis of differences between the
treatment arms, the calculation of the sample size of the
trial was based on expected local recurrence rates of 12%
in the SCRT arm compared with 7% in the RCT arm,
resulting in altogether 760 patients (Log-Rank-test, base
time: 5 years, accrual time: 6 years, follow-up: 5 years, pro-
portion loss to follow-up: 10% per arm, error of the 1st
kind: α = 5% two-sided, power = 80%). An interim analy-
sis is planned after five years study time with an error of
the 1st kind = αint = 0.5% [12].
Randomisation and stratification
Randomisation is done centrally at the clinical trial office
of the Charité Comprehensive Cancer Center, Charité,
Berlin. During randomisation patients are stratified by
centre, tumour location (below 3 cm, between 3 and 8
cm, or between 8 and 12 cm above dentate line), TN-stage
(uT2N+, T3N0, T3N+), open vs. laparoscopic surgery, and
the type of resection (abdominoperineal resection vs. low
anterior resection) according to the surgeons evaluation
prior to preoperative therapy. Minimization has been
used to ensure a balanced distribution with respect to
arms and strata [13].
Patient selection
In order to be included in the trial, patients are required
to be aged 18 years or over and to have
1. Karnofsky Index 80% or better
2. Histological proved diagnosis of rectal cancer (adeno-
or mucinous carcinoma)
3. Primary rectal cancer:
3.1. Maximum 12 cm above dentate line (upper limit)
3.2. Staged T2N+ or T3N0 or T3N+ (by endorectal ultra-
sound or Computed Tomography [CT]/Magnetic Reso-
nance Imaging [MRI] scan)
4. No evidence of metastatic disease as determined by
chest X-ray and abdominal ultrasound (or CT-scan of
chest and abdomen or other investigations such as Posi-
tron Emission Tomography [PET] scan or biopsy if
required)
5. Adequate bone marrow function with platelets more
than 100 × 10^9/l and neutrophils more than 2.0 × 10^9/
l
6. Creatinine clearance more than 50 ml/min
7. Serum bilirubin less than 2.0 × Upper Limit of institu-
tional Normal range (ULN)
8. Written informed consent is obtained prior to com-
mencement of trial treatment.
Exclusion criteria are:
1. Rectal cancer other than adeno- or mucinous carcinoma
2. Previous or concurrent malignancies, with the excep-
tion of adequately treated basal cell carcinoma of the skin
or in situ carcinoma of the cervix
3. Patients with locally advanced inoperable disease, such
as T4-tumourPage 4 of 6
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tumour
5. Any previous chemotherapy or radiotherapy, and any
investigational treatment for rectal cancer
6. Concurrent uncontrolled medical conditions
7. Pregnancy or breast feeding
8. Clinically significant (i.e. active) cardiac disease (e.g.
congestive heart failure, symptomatic coronary artery dis-
ease) or myocardial infarction within the last six months
9. Stenotic tumour which can not be passed by the colon-
oscope and pre-operative need of diverting stoma
10. Evidence of hereditary colorectal cancer (Hereditary
Non-Polyposis Colorectal Cancer [HNPCC] and Familial
Adenomatous Polyposis [FAP])
11. Medical or psychiatric conditions that compromise
the patient's ability to give informed consent
Preoperative therapy
Radiotherapy is performed according to the standardized
protocol with CT-based 3D-conformal treatment plan-
ning. The clinical target volume includes the primary
tumour, the mesorectal tissue including perirectal and
presacral nodes, and internal iliac lymph nodes [14]. The
reference dose is defined in accordance to the Interna-
tional Commission on Radiation Units and Measurement
report 50/63. All patients are irradiated in a prone posi-
tion on a belly board with a CT-planned three-field tech-
nique with megavoltage photons ≥ 6 MV. An individual
field shielding is obligatory by using a multileaf collima-
tor. SCRT consists of single doses of 5.0 Gy in five frac-
tions within one week up to a total dose of 25 Gy. For
RCT, standard fractions of 1.8 Gy/d are given 5 times a
week up to a total dose of 50.4 Gy; concomitant chemo-
therapy consists of continuous 5-FU-infusion 225 mg per
square meter per day.
Radiotherapy-related toxicities will be assessed using the
NCI Common Toxicity Criteria (CTC). Toxicity will be
evaluated weekly during the therapy and at follow-up 3
months, 6 months, 1 year, 2 years and 5 years after treat-
ment by standard forms (LENT SOMA).
Surgery and histopathological analysis
Surgical resection has to be done within 5 days after SCRT
or 5–6 weeks after the completion of RCT. The standard
surgical procedure is total mesorectal excision (TME), for
tumours located 10 cm above the anal verge a partial mes-
orectal excision (PME) is feasible; anterior resection, inter-
sphincteric resection or abdominoperineal resection is
done according to clinical staging and patient's prefer-
ence. Quality (completeness) of TME has do be evaluated
and documented by every surgeon at the resected speci-
men (by injection of methylene blue into the arteria rec-
talis superior).
The surgical specimens are processed and evaluated by
standardized pathology and including UICC TNM catego-
ries and staging groups, number of examined and
involved lymph nodes and the status of resection margins.
In addition, the CRM (circumferential resection margin)
and the TME-quality have to be documented by the
pathologist according to the British Medical Research
Council [15]. Histopathological response is deduced from
tumour regression (TRG). TRG is evaluated according the
5 point scoring system of Dworak [16].
Adjuvant chemotherapy and follow-up
2–4 weeks after complete resection continuous 5-FU infu-
sion therapy with 300 mg/m2 BSA is applied for 12 weeks
as far as there is no contraindication as serious impaired
wound healing or anastomotic leakage. Toxicity will be
evaluated during the chemotherapy and at follow-up.
Patients are included into a standardized follow-up pro-
gram according to the guidelines of the Tumorzentrum
Berlin. This includes follow-up visits at 3, 6, 12, 18 and 24
months after surgery, and then every year for a total of 5
years. Each visit includes physical examination, abdomi-
nal ultrasound, rectosigmoidoscopy and endorectal ultra-
sound (in case of sphincter saving surgery), CEA level as
well as a chest X-ray every year. In addition, pelvic CT (or
MRI) -scans are performed 3 months, 12 months, 24 and
36 months after surgery. Furthermore a complete colon-
oscopy is required 18 months, 36 months and 60 months
post treatment.
Radiotherapy-related toxicities will be assessed during
every visit using the LENT SOMA criteria.
Evaluation of quality of life is assessed by the EORTC
QLQ D30 and QLQ D 38 questionnaire at time of ran-
domisation, end of therapy, 3 and 6 months, 1 year, 3
years and 5 years after surgery.
Discussion
Both preoperative short term radiotherapy (STRT) and
neoadjuvant radiochemotherapy (RCT) provide increased
local control of rectal cancer. With the present trial (with
476 patients already enrolled and an interim analysis to
be performed at the end of 2008), we aim to definitely
clarify the role of the different preoperative therapy regi-
men in rectal cancer concerning local control as well as
long-term toxicities and overall survival. EspeciallyPage 5 of 6
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together with the so far unreleased data from the recently
closed TROG/AGITG trial with some more than 300
patients (and an almost identical study scheme) our trial
will help to finally decide on the efficacy to increase local
control, so further investigation can concentrate on
improving survival by selecting and modifying adjuvant
therapy regimen.
Metastasis free survival and overall survival are mainly
influenced by adjuvant chemotherapy in high risk
patients. Because of the fact that the histopathological
staging after RCT seems not to be a useful indicator for
adjuvant chemotherapy due to downstaging, adjuvant
chemotherapy with 5-FU is performed in both groups
independent of the histopathological staging to avoid an
adjuvant treatment bias.
In case local control will be equally influenced by both
therapy regimens, further follow-up with long-term toxic-
ities and overall survival could help to determine the best
protocol in rectal cancer treatment.
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